SK Bioscience Co (XKRX:302440) EV-to-EBIT : 195.78 (As of Jun. 05, 2024)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SK Bioscience Co's Enterprise Value is ₩2,819,485 Mil. SK Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩14,401 Mil. Therefore, SK Bioscience Co's EV-to-EBIT for today is 195.78.

The historical rank and industry rank for SK Bioscience Co's EV-to-EBIT or its related term are showing as below:

XKRX:302440' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.36 Med: 67.58 Max: 7807.77
Current: 195.78

During the past 6 years, the highest EV-to-EBIT of SK Bioscience Co was 7807.77. The lowest was 11.36. And the median was 67.58.

XKRX:302440's EV-to-EBIT is ranked worse than
96.47% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs XKRX:302440: 195.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SK Bioscience Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩3,557,034 Mil. SK Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩14,401 Mil. SK Bioscience Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.40%.

SK Bioscience Co EV-to-EBIT Historical Data

The historical data trend for SK Bioscience Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co EV-to-EBIT Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

33.03

29.66

490.30

SK Bioscience Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															49.62	7,241.54	111.64	490.30	246.99

Competitive Comparison of SK Bioscience Co's EV-to-EBIT

For the Biotechnology subindustry, SK Bioscience Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SK Bioscience Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SK Bioscience Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SK Bioscience Co's EV-to-EBIT falls into.

SK Bioscience Co EV-to-EBIT Calculation

SK Bioscience Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2819484.519	/	14401.44
	=	195.78

SK Bioscience Co's current Enterprise Value is ₩2,819,485 Mil.
SK Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩14,401 Mil.

SK Bioscience Co (XKRX:302440) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SK Bioscience Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	14401.44	/	3557033.984
	=	0.40 %

SK Bioscience Co's Enterprise Value for the quarter that ended in Mar. 2024 was ₩3,557,034 Mil.
SK Bioscience Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩14,401 Mil.

SK Bioscience Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co (XKRX:302440) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co (XKRX:302440) Headlines

No Headlines